Protagonist Therapeutics Profit Margin

Protagonist Therapeutics (PTGX) currently reports a profit margin of 35.85% as of June 2026. That compares with 25.55% in the prior-year period — up 40.3% year over year. That is above the Healthcare sector average of 14.34%. Use the charts on this page to explore Protagonist Therapeutics's profit margin history and peer comparisons.

Protagonist Therapeutics's profit margin increased from 25.55% to 35.85% — a 40.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Protagonist Therapeutics's profit margin of 35.85% is higher than the Healthcare sector average of 14.34%. That is roughly 149.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Protagonist Therapeutics's current 35.85% should be judged against Healthcare norms (sector average: 14.34%) and against PTGX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 35.85%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Protagonist Therapeutics, and consider following PTGX for alerts when major investors trade the stock.